(ERF) Eurofins Scientific SE - Ratings and Ratios
Testing, Laboratory, Diagnostics, Agroscience, Environment
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.87% |
| Yield on Cost 5y | 0.86% |
| Yield CAGR 5y | -3.08% |
| Payout Consistency | 80.3% |
| Payout Ratio | 26.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 30.9% |
| Value at Risk 5%th | 44.0% |
| Relative Tail Risk | -13.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.46 |
| Alpha | 36.63 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.520 |
| Beta | 0.097 |
| Beta Downside | 0.078 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| Mean DD | 19.08% |
| Median DD | 18.53% |
Description: ERF Eurofins Scientific SE January 03, 2026
Eurofins Scientific SE (ticker ERF) is a Luxembourg-based global provider of analytical testing and laboratory services, operating through a network of more than 800 labs in over 50 countries.
The firm’s portfolio spans agroscience (e.g., seed testing, environmental safety), consumer product testing (including sustainability certifications and sensory evaluation), biopharma and clinical diagnostics, as well as food-and-feed safety (allergen, GMO, microbiology, pesticide residues, etc.). Additional capabilities cover forensic genomics, maritime and materials testing, REACH compliance, and a suite of audit, certification, and training services.
Key financial and sector drivers: • FY 2023 revenue reached €6.1 bn, with organic growth of ~12% and an EBITDA margin of ~13%, underscoring the scalability of its lab network. • Eurofins’ growth is heavily fueled by rising regulatory scrutiny on food safety, pharmaceutical quality, and ESG compliance, which is expanding demand for third-party testing and certification. • The company’s aggressive acquisition strategy-over €1 bn of deals in the past three years-has broadened its geographic reach and deepened service breadth, positioning it as a leading contract research organization (CRO) in the biotechnology sub-industry.
For a deeper dive into Eurofins’ valuation metrics and peer comparison, you might explore the detailed analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (503.1m TTM) > 0 and > 6% of Revenue (6% = 628.0m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 4.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 5.10% (prev 9.67%; Δ -4.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 2.01b > Net Income 503.1m (YES >=105%, WARN >=100%) |
| Net Debt (3.36b) to EBITDA (2.17b) ratio: 1.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.5m) change vs 12m ago -4.61% (target <= -2.0% for YES) |
| Gross Margin 14.42% (prev 12.63%; Δ 1.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 97.48% (prev 89.74%; Δ 7.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.20 (EBITDA TTM 2.17b / Interest Expense TTM 221.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.78
| (A) 0.05 = (Total Current Assets 2.62b - Total Current Liabilities 2.09b) / Total Assets 10.59b |
| (B) 0.27 = Retained Earnings (Balance) 2.81b / Total Assets 10.59b |
| (C) 0.11 = EBIT TTM 1.15b / Avg Total Assets 10.74b |
| (D) 0.82 = Book Value of Equity 4.86b / Total Liabilities 5.91b |
| Total Rating: 2.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.83
| 1. Piotroski 7.0pt |
| 2. FCF Yield 7.65% |
| 3. FCF Margin 10.46% |
| 4. Debt/Equity 0.89 |
| 5. Debt/Ebitda 1.55 |
| 6. ROIC - WACC (= 5.01)% |
| 7. RoE 9.84% |
| 8. Rev. Trend 11.75% |
| 9. EPS Trend 8.62% |
What is the price of ERF shares?
Over the past week, the price has changed by +11.06%, over one month by +19.63%, over three months by +10.53% and over the past year by +44.47%.
Is ERF a buy, sell or hold?
What are the forecasts/targets for the ERF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.5 | -6.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 72.6 | 5.4% |
ERF Fundamental Data Overview January 06, 2026
P/E Trailing = 27.3128
P/E Forward = 14.0647
P/S = 1.5329
P/B = 2.3615
P/EG = 0.7439
Beta = 0.877
Revenue TTM = 10.47b EUR
EBIT TTM = 1.15b EUR
EBITDA TTM = 2.17b EUR
Long Term Debt = 3.58b EUR (from longTermDebt, last quarter)
Short Term Debt = 538.4m EUR (from shortTermDebt, last quarter)
Debt = 4.11b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.36b EUR (from netDebt column, last quarter)
Enterprise Value = 14.31b EUR (10.95b + Debt 4.11b - CCE 753.3m)
Interest Coverage Ratio = 5.20 (Ebit TTM 1.15b / Interest Expense TTM 221.7m)
FCF Yield = 7.65% (FCF TTM 1.10b / Enterprise Value 14.31b)
FCF Margin = 10.46% (FCF TTM 1.10b / Revenue TTM 10.47b)
Net Margin = 4.81% (Net Income TTM 503.1m / Revenue TTM 10.47b)
Gross Margin = 14.42% ((Revenue TTM 10.47b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 22.43% (prev 9.96%)
Tobins Q-Ratio = 1.35 (Enterprise Value 14.31b / Total Assets 10.59b)
Interest Expense / Debt = 1.67% (Interest Expense 68.6m / Debt 4.11b)
Taxrate = 28.79% (49.9m / 173.2m)
NOPAT = 820.8m (EBIT 1.15b * (1 - 28.79%))
Current Ratio = 1.26 (Total Current Assets 2.62b / Total Current Liabilities 2.09b)
Debt / Equity = 0.89 (Debt 4.11b / totalStockholderEquity, last quarter 4.64b)
Debt / EBITDA = 1.55 (Net Debt 3.36b / EBITDA 2.17b)
Debt / FCF = 3.07 (Net Debt 3.36b / FCF TTM 1.10b)
Total Stockholder Equity = 5.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.69% (Net Income 503.1m / Total Assets 10.59b)
RoE = 9.84% (Net Income TTM 503.1m / Total Stockholder Equity 5.11b)
RoCE = 13.26% (EBIT 1.15b / Capital Employed (Equity 5.11b + L.T.Debt 3.58b))
RoIC = 9.97% (NOPAT 820.8m / Invested Capital 8.24b)
WACC = 4.95% (E(10.95b)/V(15.06b) * Re(6.37%) + D(4.11b)/V(15.06b) * Rd(1.67%) * (1-Tc(0.29)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.33%
[DCF Debug] Terminal Value 86.32% ; FCFF base≈924.0m ; Y1≈922.1m ; Y5≈974.4m
Fair Price DCF = 145.0 (EV 28.96b - Net Debt 3.36b = Equity 25.60b / Shares 176.5m; r=6.0% [WACC]; 5y FCF grow -0.83% → 3.0% )
EPS Correlation: 8.62 | EPS CAGR: 129.9% | SUE: -4.0 | # QB: 0
Revenue Correlation: 11.75 | Revenue CAGR: 2.67% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=4.15 | Chg30d=+0.007 | Revisions Net=+0 | Growth EPS=+10.1% | Growth Revenue=+5.8%